HIP2-positive breast cancer – Available anti-HER2 therapies and new agents under investigation

Martyna Zielińska¹A-D, Natalia Zarankiewicz¹B-C, Katarzyna Kosz¹B-C, Aleksandra Kuchnicka¹B-C, Bogumiła Ciseł¹E-F

¹ Students’ Scientific Association, Oncological Surgery Department, Medical University, Lublin, Poland
² Oncological Surgery Department, Independent Public Teaching Hospital No. 1, Lublin; Medical University, Lublin, Poland
A – Research concept and design, B – Collection and/or assembly of data, C – Data analysis and interpretation, D – Writing the article, E – Critical revision of the article, F – Final approval of article

Address for correspondence: Martyna Zielińska, Students’ Scientific Association, Oncological Surgery Department, Medical University, Lublin, Poland, Poland
E-mail: martynazielińska52268@gmail.com

Abstract
Introduction and objectives. Breast cancer (BC) is the most common malignancy and the leading cause of cancer death among women. About 15–20% of all BCs are HER2-positive. Proper assessment of HER2 status is crucial to choose appropriate treatment. The review summarizes data on anti-HER2 drugs used to treat HER2-positive BC and provides basic information on new agents under investigation.

Brief description of the state of knowledge. Specific HER2-targeting drugs are available or are being evaluated in clinical trials. Anti-HER2 agents include: monoclonal antibodies, tyrosine kinase inhibitors, antibody-drug conjugates, bispecific antibodies, PI3K/AKT/mTOR inhibitors and heat shock protein 90 inhibitors, HER2-targeting vaccines and CDK4/6 inhibitors. The advent of anti-HER2 therapies increased the time of progression free survival and overall survival in BC patients.

Results. Final analysis of the CLEOPATRA trial shows that the combination of trastuzumab, pertuzumab and taxane significantly improved outcomes in metastatic HER2-positive BC and it is currently preferred first-line treatment. The recommended second-line treatment is based on trastuzumab emtansine or on the combination of lapatinib and capecitabine. Some promising agents such as margetuximab or trastuzumab deruxtecan are still under investigation.

Conclusions. Anti-HER2 directed treatment undoubtedly improves outcomes among patients with HER2-positive BC. Access to drugs such as trastuzumab, pertuzumab, lapatinib and T-DM1 improves prognosis even in patients with advanced disease. Further studies and clinical trials on novel anti-HER2 therapies are required. Nevertheless, BC treatment is becoming more effective and, hopefully, one day it may be possible to cure patients even with metastases.

Key words
breast cancer, targeted therapies, HER2-positive breast cancer, HER2-targeting treatment, anti-HER2 drugs

INTRODUCTION

Breast cancer (BC) is currently the most common malignant tumour in women worldwide. The World Health Organization (WHO) report from 2018 states that over 2 million new BC cases are diagnosed each year globally. This fact makes BC the most commonly diagnosed female cancer (24.2%). Moreover, it is also the leading cause of cancer death among women (15%) [1].

The human epidermal growth factor receptor 2 (HER2) is a membrane tyrosine kinase. Its activation impinges on cell multiplication, survival, mobility and adherence. It is estimated that HER2 over-expression occurs in around 15–20% of all BC cases. HER2-positive BCs are deemed to be more aggressive and have poorer outcomes [2].

Proper evaluation of potential HER2 over-expression determines choosing the appropriate treatment for breast cancer patients. False positive results of HER2 status may lead to unnecessary and ineffective treatment, while false negative results may cause omitting advanced, directed therapy [3]. According to the guidelines from 2013, it is recommended that HER2 testing should be performed in each new case of invasive BC as well in the case of recurrence if the specimen is accessible. There are several methods of evaluating HER2 amplification, although at present only two are validated for clinical practice [5] (Tab. 1).

<table>
<thead>
<tr>
<th>Method</th>
<th>Use in clinical practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immuno-histochemistry (IHC)</td>
<td>Authorized</td>
</tr>
<tr>
<td>In situ hybridization (ISH)</td>
<td>Authorized</td>
</tr>
<tr>
<td>PAM50 test</td>
<td>Not validated</td>
</tr>
<tr>
<td>mRNA expression profiling</td>
<td>Not validated</td>
</tr>
<tr>
<td>Mass spectrometry</td>
<td>Not validated</td>
</tr>
<tr>
<td>Serum HER2 levels</td>
<td>Not validated</td>
</tr>
</tbody>
</table>

OBJECTIVE

The aim of the review is to summarize available data on anti-HER2 drugs used in HER2-positive BC treatment and provide basic information on new agents under investigation in several clinical trials. The analysis concerned publications mainly from 2012–2019. The data was collected from PubMed,
and websites such as ClinicalTrials.gov or the World Health Organization website.

**DESCRIPTION OF THE STATE OF KNOWLEDGE**

**HER2 targeting treatment.** The invention of anti-HER2 directed treatment undoubtedly improved the outcomes among patients with HER2-positive BC. Due to applying anti-HER2 drugs in treatment, the majority of early BC patients are currently being successfully treated. There is also notable improvement in the time of progression free survival (PFS) and overall survival (OS) among HER2-positive metastatic breast cancer (MBC) patients [6]. Currently available drugs vary in mechanisms of action; however, these drugs can be generally divided into two main categories because of the mode of action. The first category contains agents using the over-expression of HER2 to identify cancer cells, in order that the delivery of anticancer effectors is carried out with great selectivity. The second category involves drugs that inhibit the oncogenic signaling pathways of HER2, resulting in decreasing cancer cell proliferation [3].

**Monoclonal antibodies (mAbs).** Anti-HER2 monoclonal antibodies use the expression of HER2 as a special target on tumour tissue. Only trastuzumab and pertuzumab remain approved mAbs for HER2-positive BC treatment. The third mAb being presently under investigation is margetuximab.

**Trastuzumab** was introduced for the first time for the HER2-positive MBC in 1998. This was a consequence of a randomized trial which indicated that adding trastuzumab to standard chemotherapy resulted in the improvement of PFS and OS in HER2-positive MBC patients [7]. Despite the fact that monotherapy with trastuzumab does not show significant efficacy, it definitely improves the efficacy of chemotherapy. Slamon *et al.* conducted a study in which patients during the first-line treatment were segregated into two groups: treated with chemotherapy alone versus with the addition of trastuzumab. The results showed a significant improvement in both PFS (7.4 vs. 4.6 months; *P* < 0.001) and OS (25.1 vs. 20.3 months; *P* = 0.01) in patients treated with the addition of trastuzumab. The most significant side-effect observed during 30 months of median follow-up was cardiac dysfunction, especially in combination with trastuzumab, anthracycline and cyclophosphamide (27%) compared to anthracycline and cyclophosphamide alone (8%) and trastuzumab and paclitaxel (8%) compared to paclitaxel alone (1%) [8]. In subsequent years, other researchers tested different combinations of trastuzumab with paclitaxel/docetaxel and carboplatin or vinorelbine. These combinations can be also taken into consideration while deciding on first-line treatment [6]. German Breast Group 26 tested the use of trastuzumab with capcitabine in comparison to capcitabine alone in HER2-positive BC patients after progression during trastuzumab treatment. The findings of this study showed an improvement in overall response and PFS, although not statistically significant in OS [9].

**Pertuzumab** is humanized mAb varying from trastuzumab due to binding to a distinct HER2 epitope [6]. It prevents homodimer and heterodimer formations and blocks HER2/HER3 heterodimers which activate cancer cell proliferation and survival [10]. The study using pertuzumab alone compared to pertuzumab with cytostatics in patients with progression after therapy with trastuzumab showed no desired effect [11]. The CLEOPATRA trial tested the addition of pertuzumab to the basic therapy scheme which consists of docetaxel and trastuzumab. The control group was treated with trastuzumab, docetaxel and placebo and in the research group placebo was replaced by pertuzumab. The addition of pertuzumab to standard treatment resulted in prolongation of both PFS (18.5 vs. 12.4 months, *P* < 0.001) and OS (56.5 vs. 40.8 months, *P* < 0.001) in a median follow-up of 50 months [12, 13]. The final data of the CLEOPATRA trial, published in 2019, states that 37% of patients treated in experimental arm were still alive, whereas only 23% survived in the control group. Using pertuzumab resulted in 57.1 months of median OS [14]. Pertuzumab improved the efficacy of trastuzumab. At the present time, trastuzumab with a taxane and pertuzumab remain the first-line treatment in patients with HER2-positive MBC.

**Margetuximab** is a novel antibody derived from trastuzumab and binding to the same epitope. This mAb has an optimized Fc domain which enables binding to the Fcγ receptor IIIA (CD16A) forms with high and low chemical attraction. Moreover, it demonstrates reduced affinity to an inhibitory receptor FcγRIIB (CD32B). These properties of margetuximab enable its binding to effector cells with greater efficacy and enhance antibody-dependent cellular cytotoxicity (ADCC) [10]. Margetuximab alone showed a promising activity and it was generally well tolerated [15]. The SOPHIA trial is currently ongoing. During this research, authors tested the combination of chemotherapy with trastuzumab versus with margetuximab as a third-line treatment in HER2-positive BC [16].

**Tyrosine kinase inhibitors (TKIs).** Tyrosine kinase inhibitors are small agents which preclude phosphorylation and block the pathways of HER2 signalling. Consequently, this results in a decrease of cancer cell proliferation and promotes apoptosis [17]. Among TKIs, lapatinib and neratinib are registered. Other representatives of this group have been evaluated in several clinical trials.

**Lapatinib** is the first known TKI used in the treatment of breast cancer, inhibiting both HER2 and EGFR kinases. Geyer *et al.* investigated lapatinib plus capcitabine in comparison to capcitabine alone in patients suffering from HER2-positive breast cancer who experienced progression on trastuzumab. The results showed PFS enhancement (8.4 vs. 4.4 months; *P* < 0.001) by adding lapatinib to capcitabine therapy [18].

**Second-generation TKIs** are characterized by a higher chemical attraction to the kinase domain and possibly a wider range of activity.

**Neratinib** is the first representative, which irreversibly inhibits pan-HER receptor tyrosine kinases [19]. One study reported that neratinib monotherapy showed that in patients non-treated previously with trastuzumab, 16-week PFS was greater compared to women with previous trastuzumab-based therapy (78% vs. 59%). The most common side-effect of neratinib was diarrhea (13–30% of patients) [20]. Results of another临床 trial assessing the influence of neratinib-
capcitabine treatment after trastuzumab showed 40.3 weeks of median PFS in patients not previously treated with lapatinib, and 35.9 weeks in patients after lapatinib therapy [21]. The NEFERT-T Randomized Clinical Trial reported that as the first-line therapy, trastuzumab-paclitaxel out-performed neratinib-paclitaxel, although it showed that neratinib-paclitaxel may decrease the incidence of central nervous system progression. However, large-scale randomized trials are required to confirm these results [22].

The ExeNET trial investigated neratinib as the next treatment after trastuzumab-based line in patients with HER2-positive early BC. The results showed a reduction of 33% of invasive recurrence risk in a three years median follow-up [23]. Based on these results, the FDA recently authorized neratinib for patients with HER2-positive early BC as an additional adjuvant treatment [10]. Another study, the NALA trial, is evaluating the use of lapatinib versus neratinib, both in combination with capcitabine in HER2-positive MBC patients [24].

**Afatinib** is the next generation TKI. The Lux-Breast III trial evaluated afatinib-containing treatments among patients with HER2-positive metastatic breast cancer and brain metastasis. Benefits of afatinib therapy did not differ from other choices of treatments. Moreover, afatinib caused more adverse effects and was less well tolerated [25]. In several studies, adverse effects of afatinib, such as diarrhea or rash, were the reason to discontinue investigation of this agent, especially as there was insufficient clinical benefit. No clinical trial on the use of afatinib in HER2-positive BCs are being undertaken at present [19].

**Tucatinib** – an ONT-380 molecule, is another second-generation TKI under clinical evaluation. It selectively inhibits HER2, with no substantial influence on HER1. The results of the phase I trial on HER2-positive MBC patients indicate a clinical benefit rate (CBR) of 27%. At present, this drug causes less severe adverse effects than neratinib or afatinib [19]. The combination of trastuzumab and capcitabine, with or without tucatinib, is currently being evaluated in the HER2CLIMB trial, which is addressed to patients suffering from HER2-positive BC with and without brain metastases [26]. Another study tested tucatinib combined with T-DM1 in HER2-positive MBC patients which included 30 patients with brain metastases. The brain-specific overall response rate was 36%, median PFS – 6.7 months. **Pyrotinib** and **poziotinib** are two more novel TKIs under investigation in clinical trials [10].

**Antibody-drug conjugates** (ADCs) consist of three elements: mAb, linker, chemotherapy payload. Specific antibody recognizes targeted cells and a payload attacks these cells in several mechanisms. In BC treatment, the mAb used in designing ADCs is usually trastuzumab [3].

**Trastuzumab emtansine** (T-DM1) is currently the only ADC registered for HER2-positive BC treatment. It consists of trastuzumab and maytansine derivate (DM1), a cytotoxic agent that inhibits mitosis through disrupting microtubules in cancer cells [10]. The EMILIA trial compared the use of T-DM1 and lapatinib-capcitabine in women after progression on trastuzumab-taxane. Analysis showed both PFS and OS were longer with T-DM1 (9.6 months and 29.9 months, respectively) than with lapatinib-capcitabine (6.4 months and 25.9 months, respectively) [27,28]. According to these results, in 2013, the FDA approved T-DM1 for treatment in HER2-positive MBC patients who have progressed on therapy with trastuzumab and docetaxel [3]. This is currently the standard in second-line therapy for patients with HER2-positive BC. In compliance with the results of the TH3RESA trial, T-DM1 could be an option for the treatment of patients who experience progression beyond second-line HER2-directed treatment if they had not yet received T-DM1 [29]. However, based on the findings of the MARIANNE trial, T-DM1 in not preferred as a first-line treatment. Neither T-DM1 alone nor T-DM1-pertuzumab showed superiority to trastuzumab-taxane [30].

**Trastuzumab deruxtecan** (DS-8201a), another ADC, is presently under investigation. It comprises anti-HER2 monoclonal antibody trastuzumab and exatecan derivative, which inhibits topoisomerase I. Results of preclinical studies showed that DS-8201a is active not only against HER2-positive tumours, but also against low HER2-expressing cancers [10]. This fact makes DS-8201a superior to T-DM1, which does not show anti-tumour activity if tumours show a low expression of HER2. The overall response rates (ORR) after administering trastuzumab-deruxtecan among prior treated MBC patients with HER2 over-expression and in low HER2-expressing cases, were 54.5% and 50%, respectively. It was relatively safe because it mainly caused nausea, decreased appetite and vomiting [31]. Currently, trastuzumab deruxtecan is being investigated in two phase III clinical trials – DESTINY-Breast02 and DESTINY-Breast03 [32, 33].

**SYD985** is another investigated ADC, based on trastuzumab linked to prodrug DUBA SYD 986 (seco-Duocarmycin-hydroxyBenzamide-Azaindole). Its mechanism of action is based on causing irreversible DNA alkylation and consequently death of both dividing and non-dividing cells of a tumour and of neighboring tumour cells. Preclinical results of SYD985 in BC are impressive [3, 10]. The development of this drug is ongoing in phase III TULIP trial [34]. Other ADCs are also currently under investigation in several clinical trials [35–39] (Tab. 2).

**Table 2. ADCs under investigation**

<table>
<thead>
<tr>
<th>Drug</th>
<th>ClinicalTrials.gov Identifier</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trastuzumab deruxtecan (DS-8201a)</td>
<td>NCT03523585</td>
<td>Phase 3</td>
</tr>
<tr>
<td></td>
<td>NCT03529910</td>
<td>Phase 3</td>
</tr>
<tr>
<td>SYD985</td>
<td>NCT03262935</td>
<td>Phase 3</td>
</tr>
<tr>
<td>RC48-ADC</td>
<td>NCT02881138</td>
<td>Phase 1</td>
</tr>
<tr>
<td>PF-06804103</td>
<td>NCT03284723</td>
<td>Phase 1</td>
</tr>
<tr>
<td>ARX788</td>
<td>NCT02512237</td>
<td>Phase 1</td>
</tr>
<tr>
<td>MEDI4276</td>
<td>NCT02576548</td>
<td>Phase 1</td>
</tr>
<tr>
<td>XMT-1522</td>
<td>NCT02952729</td>
<td>Phase 1</td>
</tr>
</tbody>
</table>

**PI3K/AKT/mTOR inhibitors and heat shock protein 90 (HSP90) inhibitors.** Understanding the signaling pathways of the HER receptors may contribute positively to developing specific inhibitors of several molecular pathways. The PI3K/AKT/mTOR pathway is the main pathway being investigated for anti-HER2 therapies. It is known that PIK3CA mutations occur in about one-third of patients with HER2-positive breast cancers. This may be related to worse prognosis [40].
Combinations of various inhibitors of this pathway with standard treatments have been tested or are still being tested in several clinical trials. Two clinical trials (BOLERO-1 and BOLERO-3) have not confirmed the effectiveness of the combination of mTOR inhibitor everolimus with standard anti-HER2 therapies [41, 42]. However, subsequent analysis of these two trials suggests that some patients (for example, with PIK3CA mutations) may benefit from everolimus [43].

**Alpelisib** is the next representative of this group of agents. It is an α-specific PI3K inhibitor. Combining alpelisib and T-DM1 resulted in 10.6 months of median PFS in phase I trial, and will be continued in phase II [3]. Another phase I trial on alpelisib in combination with trastuzumab and HER3 inhibitor LJM716 in patients with HER2-positive advanced BC is ongoing (ClinicalTrials.gov identifier: NCT02167854) [44]. Other PI3K inhibitors being currently evaluated are copanlisib (ClinicalTrials.gov identifier: NCT02705859), taselisib (ClinicalTrials.gov identifier: NCT02390427) or buparlisib [3, 45, 46]. None of PI3K inhibitors is currently registered.

The regulation of HER2 receptors expression is another approach to anti-HER2 therapy. There were presented some encouraging results when ganetespib (heat shock protein 90 (HSP90) inhibitor) was combined with trastuzumab and paclitaxel administered once a week in MBC cases. In two of nine patients, partial tumour response was obtained (overall response rate: 22%), five patients achieved disease stability (rate: 56%), which lasted from 11 – 29 weeks, clinical benefit rate – 44%. The combination of these three drugs warrants further study [47].

**Bispecific antibodies (BsAbs)**, defined as agents capable of binding to two different types of antigen simultaneously, for instance, an antigen of cytotoxic cell and an antigen expressed by a cancer cell. This may be the next mechanism of action of anticancer drugs. The main representative of BsAbs is ertuxamomab. This is a trifunctional BsAb that targets HER2, CD3 antigen specific to T-cells and the Fcγ receptors I, IIa, and III. The first trial of ertuxamomab showed an anti-tumour response in 33% of patients. Further investigation of ertuxamomab is required [19]. Other representatives of BsAbs under clinical development are MCLA-128, ZW25, GBR1302, PRS-343 [10].

**CDK4/6 inhibitors.** The addition of CDK4/6 inhibitors to the standard treatment of HER2-positive BC may have a positive influence in overcoming acquired resistance to anti-HER2 therapies [48]. Two main clinical studies investigating the role of these agents in HER2-positive BC are the PATINA study and the MonarCHer study. The PATINA study assesses the usage of palbociclib in combination with trastuzumab, pertuzumab and an aromatase inhibitor [49]. The MonarCHer study is addressed to previously treated MBC patients and explores the influence of the combination of abemacilcil and trastuzumab [50].

**HER2-targeting vaccines.** HER2-targeting vaccines are being evaluated at present in several clinical trials. One is testing the HER2 vaccine NeuVaxTM, which consists of Nelipepimut-S or E75 peptide and granulocyte macrophage-colony stimulating factor. The study is evaluating the use of this vaccine in combination with trastuzumab in HER2-positive BC patients (ClinicalTrials.gov identifier: NCT02297698) [51]. Another vaccine under investigation in a phase I trial is ETBX-021. The role of this vaccine is being tested in low-expressing HER2 BC patients [10].

**CONCLUSIONS**

The development of possible methods of treatment in oncology results in prolongation of the time of survival among patients suffering from malignancies. Breast cancer patients also experience increasingly better outcomes. Due to the discovery of HER2-targeting therapies, a significant improvement is observed in PFS and OS among HER2-positive BC patients. Access to drugs, such as trastuzumab, pertuzumab, lapatinib and T-DM1, enables patients to live a relatively normal life, even in those with advanced disease. Moreover, final analysis of the some clinical trials show that breast cancer is becoming the chronic disease. Novel drugs are being evaluated in many clinical trials and many of them are already showing promising results. It is hoped that in the future it may be possible to cure even metastatic cases of breast cancer.

**REFERENCES**


ClinicalTrials.gov. DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]. www.clinicaltrials.gov/ct2/show/NCT03523585.


